Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Global Oncology Drugs Market to Surpass US$ 301.8 Billion by 2030 - Coherent Market Insights | ||
By: PR Newswire Association LLC. - 08 Aug 2022 | Back to overview list |
|
SEATTLE, Aug. 8, 2022 /PRNewswire/ -- According to Coherent Market Insights, the global oncology drugs market is estimated to be valued at US$ 119.0 billion in 2022 and is expected to exhibit a CAGR of 12.3 % during the forecast period (2022-2030). Key Trends and Analysis of the Global Oncology Drugs Market: Major players operating in market are focusing on adopting strategies such as product approvals, which is expected to drive the market growth over the forecast period. For instance, on June 4 2022, The World Health Organization (WHO), collaborated with the American Society of Clinical Oncology (ASCO), association of physicians and oncology professionals, to develop and promote cancer care innovations that are specifically designed to enhance health outcomes, and take account of the contexts in which patients live. Furthermore, in September 2021, Secura Bio, Inc.,an integrated pharmaceutical company dedicated to the worldwide development and commercialization of impactful oncology therapies, announced that it has entered into a distribution agreement for COPIKTRA (duvelisib) with Clinigen Group Plc (Clinigen), a global, specialist pharmaceutical services and products company, covering 39 countries in Europe including Austria, Belgium, Croatia, Czech Republic, Denmark, Finland, France, Greece, Hungary, Ireland, Italy, The Netherlands, Poland, Portugal, Spain, Sweden, and Switzerland. Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/2332 Key Market Takeaways:
Request for Customization @ https://www.coherentmarketinsights.com/insight/request-customization/2332 Detailed Segmentation: Global Oncology Drugs Market, By Drug type:
Global Oncology Drugs Market, By Cancer type:
Global Oncology Drugs Market, By Distribution Channel:
Global Oncology Drugs Market, By Region:
Buy this Complete Report Now @ https://www.coherentmarketinsights.com/insight/buy-now/2332 Find related trending report below: India Immuno-Oncology Drugs Market, by Drug Type (Immune Checkpoint Inhibitors (Nivolumab, Atezolimumab, Pembrolizumab, Durvalumab), Monoclonal Antibodies (Rituximab, Trastazumab, Bevacizumab , Nimotuzumab, Pertuzumab, Ado-Trastuzumab Emtansine ), and Cancer Vaccines (Gardasil, Cervarix), by Cancer Type (Lung Cancer, Blood Cancer, Breast Cancer, Ovarian Cancer, Cervical Cancer, Colorectal Cancer, Stomach Cancer, Head & Neck Cancer, and Others), and by Distribution Channel (Online Pharmacies, Retail Pharmacies, and Hospital Pharmacies) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028 About Us: Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients. Contact Us: Mr. Shah Logo: https://mma.prnewswire.com/media/902389/Coherent_Market_Insights_Logo.jpg View original content:https://www.prnewswire.com/news-releases/global-oncology-drugs-market-to-surpass-us-301-8-billion-by-2030--coherent-market-insights-301601413.html SOURCE Coherent Market Insights |
||
|
||
Copyright 2022 PR Newswire Association LLC. | Back to overview list |